Logo image of JMP

JMP Group Inc (JMP) Stock Fundamental Analysis

NYSE:JMP - New York Stock Exchange, Inc. -

7.5  +0.02 (+0.27%)

After market: 7.49 -0.01 (-0.13%)

Fundamental Rating

2

JMP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 229 industry peers in the Capital Markets industry. Both the profitability and financial health of JMP have multiple concerns. JMP is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JMP was profitable.
JMP Yearly Net Income VS EBIT VS OCF VS FCFJMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 10M -10M 20M -20M

1.2 Ratios

Industry RankSector Rank
ROA 4.71%
ROE 15.12%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JMP Yearly ROA, ROE, ROICJMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -5 -10 -15

1.3 Margins

Industry RankSector Rank
OM 9.63%
PM (TTM) 6.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JMP Yearly Profit, Operating, Gross MarginsJMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 20 40 60 80

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, JMP has more shares outstanding
Compared to 1 year ago, JMP has an improved debt to assets ratio.
JMP Yearly Shares OutstandingJMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M
JMP Yearly Total Debt VS Total AssetsJMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 200M 400M 600M 800M 1B

2.2 Solvency

A Debt/Equity ratio of 1.03 is on the high side and indicates that JMP has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
JMP Yearly LT Debt VS Equity VS FCFJMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 50M 100M 150M

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A

More info and screens

7

3. Growth

3.1 Past

JMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9800.00%, which is quite impressive.
Measured over the past years, JMP shows a decrease in Earnings Per Share. The EPS has been decreasing by -6.33% on average per year.
Looking at the last year, JMP shows a very strong growth in Revenue. The Revenue has grown by 99.21%.
The Revenue has been decreasing by -6.66% on average over the past years.
EPS 1Y (TTM)9800%
EPS 3Y-3.03%
EPS 5Y-6.33%
EPS Q2Q%123.08%
Revenue 1Y (TTM)99.21%
Revenue growth 3Y-7.62%
Revenue growth 5Y-6.66%
Sales Q2Q%58.42%

3.2 Future

Based on estimates for the next years, JMP will show a very strong growth in Earnings Per Share. The EPS will grow by 30.69% on average per year.
JMP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.95% yearly.
EPS Next Y35.21%
EPS Next 2Y6.79%
EPS Next 3Y21.98%
EPS Next 5Y30.69%
Revenue Next Year65.99%
Revenue Next 2Y28.13%
Revenue Next 3Y29.13%
Revenue Next 5Y29.95%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JMP Yearly Revenue VS EstimatesJMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
JMP Yearly EPS VS EstimatesJMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0.5 1 1.5

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 7.58 indicates a rather cheap valuation of JMP.
Compared to an average S&P500 Price/Earnings ratio of 25.05, JMP is valued rather cheaply.
JMP is valuated reasonably with a Price/Forward Earnings ratio of 10.61.
JMP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.07.
Industry RankSector Rank
PE 7.58
Fwd PE 10.61
JMP Price Earnings VS Forward Price EarningsJMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.18
JMP Per share dataJMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
JMP's earnings are expected to grow with 21.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.22
PEG (5Y)N/A
EPS Next 2Y6.79%
EPS Next 3Y21.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JMP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

JMP Group Inc

NYSE:JMP (11/15/2021, 8:51:24 PM)

After market: 7.49 -0.01 (-0.13%)

7.5

+0.02 (+0.27%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners0.82%
Ins Owner Change0%
Market Cap157.82M
Analysts45
Price Target7.65 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 7.58
Fwd PE 10.61
P/S 0.9
P/FCF N/A
P/OCF N/A
P/B 2.24
P/tB N/A
EV/EBITDA 8.18
EPS(TTM)0.99
EY13.2%
EPS(NY)0.71
Fwd EY9.43%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.29
BVpS3.35
TBVpSN/A
PEG (NY)0.22
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.71%
ROE 15.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 9.63%
PM (TTM) 6.1%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9800%
EPS 3Y-3.03%
EPS 5Y-6.33%
EPS Q2Q%123.08%
EPS Next Y35.21%
EPS Next 2Y6.79%
EPS Next 3Y21.98%
EPS Next 5Y30.69%
Revenue 1Y (TTM)99.21%
Revenue growth 3Y-7.62%
Revenue growth 5Y-6.66%
Sales Q2Q%58.42%
Revenue Next Year65.99%
Revenue Next 2Y28.13%
Revenue Next 3Y29.13%
Revenue Next 5Y29.95%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A